Production (Stage)
Zentalis Pharmaceuticals, Inc.
ZNTL
$1.20
-$0.04-3.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -33.76% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -33.76% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -33.76% | -- | -- | -- | -- |
| SG&A Expenses | 28.61% | 35.37% | 7.36% | 17.46% | 7.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.59% | 0.37% | 5.07% | 13.90% | 8.51% |
| Operating Income | 6.19% | 26.18% | 11.99% | 3.79% | 8.79% |
| Income Before Tax | -2.09% | 43.43% | 37.64% | 32.10% | 9.09% |
| Income Tax Expenses | 106.01% | 129.45% | 129.90% | 130.02% | -43.65% |
| Earnings from Continuing Operations | -2.37% | 43.26% | 37.37% | 31.75% | 9.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.00% | -75.44% | -52.38% | -67.71% | -47.89% |
| Net Income | -2.41% | 43.24% | 37.37% | 31.73% | 9.15% |
| EBIT | 6.19% | 26.18% | 11.99% | 3.79% | 8.79% |
| EBITDA | 6.17% | 26.28% | 12.02% | 3.77% | 8.81% |
| EPS Basic | 6.21% | 48.92% | 45.69% | 43.02% | 22.09% |
| Normalized Basic EPS | -12.78% | 39.57% | 43.07% | 40.13% | 38.78% |
| EPS Diluted | 6.27% | 48.91% | 45.69% | 43.02% | 22.11% |
| Normalized Diluted EPS | -12.76% | 39.55% | 43.06% | 40.12% | 38.77% |
| Average Basic Shares Outstanding | 4.38% | 8.72% | 14.09% | 20.58% | 21.21% |
| Average Diluted Shares Outstanding | 4.27% | 8.83% | 14.21% | 20.71% | 21.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |